ProfileGDS5678 / 1452436_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 90% 93% 94% 95% 93% 91% 93% 94% 92% 94% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.0578394
GSM967853U87-EV human glioblastoma xenograft - Control 27.9773893
GSM967854U87-EV human glioblastoma xenograft - Control 37.8249393
GSM967855U87-EV human glioblastoma xenograft - Control 47.4768990
GSM967856U87-EV human glioblastoma xenograft - Control 57.873593
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8759294
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3491695
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7619393
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.383591
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7855593
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.0484294
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6606892
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0929594
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8101193